SAN FRANCISCO, Sept. 16, 2024 /PRNewswire/ — Darmiyan, Inc., a pioneer in brain technology, is proud to announce the launch of the BrainSee Platform, integrating the first-of-its-kind FDA-approved BrainSee Test for Alzheimer’s disease. This innovative platform is designed to revolutionize how individuals with memory concerns assess and monitor their risk of progression to Alzheimer’s dementia within the next five years.
Darmiyan, Inc. Announces Launch of Groundbreaking BrainSee Platform for Alzheimer’s Testing
